Pressemitteilungen zu dem Thema biopharmaceutical


Unterkategorien

PresseMitteilungen zu dem Schlagwort biopharmaceutical


PAREXEL Appoints Jamie Macdonald as Chief Executive Officer

BOSTON, March 6, 2018 - PAREXEL International Corporation, the world''s leading innovator of biopharmaceutical services, today announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018. Josef von Rickenbach, who co-founded the Company, will retire from his daily CEO duties and continue as Chairman of the Board. "It is a tremendous honor for me to join PAREXEL," said Jamie Macdonald. "As a trail blazer in the biopharmaceutic ...


06.03.2018

PAREXEL Introduces Biological Sample Lifecycle Management Service to Address Growing Demand Across Drug Development

BOSTON, February 12, 2018 - PAREXEL International Corporation, the world''s leading innovator of biopharmaceutical services, today launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples. The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection at site, through in-study laboratory analysis, data generation and future u ...


12.02.2018

PAREXEL Launches Real-World Data Service Offering to Drive Value Demonstration of New Treatments

Integrated offering to be provided by new dedicated service group under PAREXEL® Access BOSTON, September 6, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value. “In an increasingly competitive market, leveraging data to demonstrate value is critical. How ...


06.09.2017

Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection

ATLANTA, GA and BOTHELL, WA -- (Marketwired) -- 08/15/17 -- Cocrystal Pharma, Inc. (OTCQB: COCP), a clinical stage biopharmaceutical company focused on developing innovative antiviral therapeutics, today announced the successful completion and positive data from the Phase 1a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus (HCV)-infected individuals. CC-31244 is a broad-spectrum, potent NS5B non-nucleoside inhibitor (NNI) of HCV replication ...


15.08.2017

PAREXEL Expands Managed Access Programs Service Offering

Simplified, end-to-end solution will help biopharmaceutical clients provide compassionate access to their treatments for patients London, January 26, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an expanded Managed Access Programs service. PAREXEL now offers end-to-end expertise for the design, development, and delivery of managed access programs to help biopharmaceutical companies provide access to investigational ...


26.01.2017

PAREXEL Launches IDMP-Focused Software And Service Solution

Solution developed to help biopharmaceutical companies meet emerging regulatory requirements ahead of deadline LONDON, November 14, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched an Identification of Medicinal Products (IDMP)-focused solution for biopharmaceutical companies. LIQUENT InSight® for IDMP™ is the newest module added to PAREXEL’s Regulatory Information Management (RIM) platform. Beginning in 2018, the Eu ...


14.11.2016

PAREXEL Launches Active Tracking Service For Monitoring And Managing Temperature-Controlled Investigational Medicinal Products

BOSTON, October 6, 2016 — PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced the launch of its Active Tracking service. The service follows Good Distribution Practice (GDP) requirements by providing biopharmaceutical companies with near real-time temperature and location monitoring of investigational medicinal products (IMPs) from central distribution centers to clinical trial sites. An increasing number of medicinal produ ...


06.10.2016

PAREXEL Announces Execution Of Definitive Agreement To Acquire ExecuPharm

Acquisition will strengthen and add scale to current functional services offering to meet growing demand London, UK: September 26, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has entered into a definitive agreement to acquire ExecuPharm, Inc. (“ExecuPharm”), a leading, global functional service provider (FSP) serving the biopharmaceutical industry. The acquisition is expected to close in the next ...


26.09.2016

Introducing EAG Laboratories; EAG Inc. Unifies Brands to Leverage Global Footprint and Full Breadth of Contract Research and Testing Capabilities

SAN DIEGO, CA -- (Marketwired) -- 07/12/16 -- EAG Inc., a global scientific services company that serves a vast array of technology- and life science-related industries, today announced that it has combined its 11 market-facing brands under a singular entity: EAG Laboratories. Following multiple acquisitions in recent years, the move is designed to bring together broad capabilities in the materials, engineering and life sciences sectors. EAG Laboratories will leverage scientific talent in its 2 ...


12.07.2016

EAG Inc. Announces Additional Investments to Enhance ABC Laboratories'' Biopharmaceutical Characterization Capabilities

SAN DIEGO, CA -- (Marketwired) -- 05/18/16 -- EAG Inc. announced today a major investment in ABC Laboratories'' capacity and analytical capabilities to meet the pharmaceutical industry''s need for high-end biopharmaceutical analysis. The announcement is part of a 2016 multimillion-dollar capital investment in instrumentation, which comes in the wake of ABC''s acquisition by California-based EAG in July of last year."The pharmaceutical industry has a critical n ...


18.05.2016

Mount Tam Biotechnologies, Inc. Announces the Appointment of Jim Stapleton as Chief Financial Officer

NOVATO, CA -- (Marketwired) -- 04/22/16 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM) is pleased to announce that effective May 2 Jim Stapleton will assume the role of Chief Financial Officer ("CFO"). Mr. Stapleton succeeds current interim CFO David R. Wells.Richard Marshak, Chief Executive Officer of Mount Tam, said, "We are excited to bring Jim on board given his impressive background and track record of success. With Jim as CFO we will be focusing ...


22.04.2016

PAREXEL And EMC Form Alliance To Provide Cloud-Based Document And Regulatory Information Management Services

LONDON, 13th April, 2016 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, and EMC Corporation (NYSE: EMC) today announced they have entered into an alliance to offer an end-to-end Regulatory Information Management (RIM) and Regulatory Content Management solution. By combining PAREXEL® LIQUENT InSight® Regulatory Information Management platform and EMC® Documentum® for Life Sciences software solution suite, PAREXEL now provides life sc ...


13.04.2016

Mount Tam Biotechnologies, Inc. Announces the Appointment of Richard Marshak as CEO

NOVATO, CA -- (Marketwired) -- 03/24/16 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK: MNTM) is pleased to announce that Dr. Richard Marshak has assumed the role of CEO, effective immediately. Dr. Marshak succeeds interim CEO Dr. Tim Powers, who remains on the Board of Directors and continues to oversee product development as Chief Scientific Officer.Brian Kennedy, Ph.D., Chairman of Mount Tam, and CEO of the Buck Institute for Research on Aging, said, "We are excite ...


24.03.2016

Pharma-Biotech Industry Capital Investment Tops $5 Billion for First-Quarter 2016 North American Project Starts, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwired) -- 01/15/16 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- As the first quarter of 2015 gathers steam, the is projected to launch over $5 billion worth of North American projects through the end of March. A healthy cash injection of that magnitude is cause for jubilation, or at the least, cautious optimism. This robust investment of capital and maintenance dollars represents a 100% leap over the first-quarter 2015 figure of $2.5 ...


15.01.2016

Cortex Pharmaceuticals, Inc. to Present at the 14th Annual BIO Investor Forum

GLEN ROCK, NJ -- (Marketwired) -- 10/19/15 -- Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, particularly obstructive and central sleep apneas and drug-induced respiratory depression, announces that it will be presenting at the 14th Annual BIO Investor Forum (). The conference is being sponsored by the Biotechnology Industry Organization and is being held on October 20 - 21, 2015 at the Parc 55 ...


19.10.2015

Cortex Pharmaceuticals, Inc. to Present at Rodman & Renshaw 17th Annual Global Investment Conference

GLEN ROCK, NJ -- (Marketwired) -- 09/08/15 -- Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, particularly obstructive sleep and central apneas and drug-induced respiratory depression, announces that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference (). The conference is being sponsored by H.C. Wainwright & Co. and is being held on September 8 - 10, 20 ...


08.09.2015

Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc.

NEW YORK, NY -- (Marketwired) -- 09/02/15 -- . announces it initiated coverage of .. (NASDAQ: OPXA), headquartered in The Woodlands, Texas, aims to commercialize its personalized T-cell immunotherapy platform for autoimmune diseases, potentially developing multiple drug candidates tailored specifically for individual patients. The company''s lead product candidate is Tcelna, now under study in a phase IIb trial as a treatment for secondary progressive multiple sclerosis (SPMS). That t ...


02.09.2015

Cortex Pharmaceuticals, Inc. Announces Initial Closing of Private Placement

GLEN ROCK, NJ -- (Marketwired) -- 08/31/15 -- Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company") today announced an initial closing of $721,180 under a private placement of up to $3 million of units at $0.02103 per unit. The Company sold 34,292,917 units, consisting of one share of common stock and one warrant to purchase two additional shares of common stock. The warrants are exercisable through September 30, 2020 and entitle the holders thereof to purch ...


31.08.2015

Cortex Pharmaceuticals, Inc. Announces Appointment of James S. J. Manuso, Ph.D., as President and Chief Executive Officer, Vice Chairman of the Board of Directors

GLEN ROCK, NJ -- (Marketwired) -- 08/19/15 -- Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company"), a leader in the discovery and development of innovative pharmaceuticals for the treatment of breathing disorders, today announced the appointment of James S. J. Manuso, Ph.D., 66, as President and Chief Executive Officer, as well as Vice Chairman and a member of the Board of Directors, of the Company. Dr. Manuso also has agreed to subscribe to purchase newly ...


19.08.2015

StockNewsNow.com Publishes New SNNLive Video Interview With Provectus Biopharmaceuticals, Inc.

LOS ANGELES, CA -- (Marketwired) -- 07/28/15 -- , the Official MicroCap News Source, today published an SNNLive Video Interview with Peter R. Culpepper, CFO and COO of Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), specializes in developing oncology and dermatology therapies, according to the company''s website (see here: ). The video interview was recorded at the Growth Capital Expo 2015 in Las Vegas, NV.Click the following link to watch the SNNLive Video Interview on StockNews ...


28.07.2015

Cortex Pharmaceuticals, Inc. Announces Partnership With the Knowledge Translation Strategy Unit of the Canadian Institutes of Health Research on the Use of Ampakines in the Alleviation of Respiratory Depression

GLEN ROCK, NJ -- (Marketwired) -- 06/30/15 -- Cortex Pharmaceuticals, Inc. (OTCQB: CORX) ("Cortex" or the "Company") is a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced respiratory depression. The Company owns patents and patent applications for certain families of chemical compounds that claim the chemical structures and their use in the treatment of various disorders. These patents cover, among other compounds, the Company& ...


30.06.2015

Serenus Biotherapeutics Enters Equity Purchase and Acquisition Agreement With Ireland-Based Global Life Sciences Company

SAN FRANCISCO, CA and JOHANNESBURG, SOUTH AFRICA -- (Marketwired) -- 03/03/15 -- Serenus Biotherapeutics, Inc., a specialty biopharmaceutical company bridging the divide between the world''s leading pharmaceutical markets and the growing demand for access to innovative therapies in the emerging nations of Africa, today announced it had secured investment of up to $43 million from Malin Corporation plc, an Ireland-based global life sciences company focused on healthcare.Under the terms ...


03.03.2015

DGAP-News: Keryx Biopharmaceuticals Provides Update From Ongoing Zerenex(TM) (ferric citrate coordination complex) Long-Term Safety Extension Study in Patients With Hyperphosphatemia on Dialysis

Keryx Biopharmaceuticals, Inc. 08.11.2013 14:30 --------------------------------------------------------------------------- Data to Date Support Results From Long-Term Phase 3 Study NEW YORK, 2013-11-08 14:30 CET (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced preliminary, unaudited data from an ongoing 48-week safety extension study of Zerenex(tm) (ferric citrate coordination complex) the Company's drug candidate for the treatment of hyperphosphatemia i ...


08.11.2013

DGAP-News: Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and

Keryx Biopharmaceuticals, Inc. 05.11.2013 13:30 --------------------------------------------------------------------------- Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients With Elevated Serum Phosphorus and Iron Deficiency Anemia Highly Statistically Significant Differences Observed in Serum Phosphorus, TSAT, Ferritin, Hemoglobin and F ...


05.11.2013

DGAP-News: Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus an

Keryx Biopharmaceuticals, Inc. 04.11.2013 23:00 --------------------------------------------------------------------------- Keryx Biopharmaceuticals to Hold Conference Call Tomorrow, November 5, 2013, at 8:30AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 2 Study of Non-Dialysis Dependent Chronic Kidney Disease Patients with Elevated Serum Phosphorus and Iron Deficiency Anemia NEW YORK, 2013-11-04 23:00 CET (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, I ...


04.11.2013

DGAP-News: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex(TM) New Drug Application

Keryx Biopharmaceuticals, Inc. 21.10.2013 14:30 --------------------------------------------------------------------------- NEW YORK, 2013-10-21 14:30 CEST (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014, for the Company's New Drug Application (NDA) for Zerenex(TM) (ferric citrate coordination complex), the Company's drug candi ...


21.10.2013

DGAP-News: Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013

Keryx Biopharmaceuticals, Inc. 17.10.2013 14:30 --------------------------------------------------------------------------- NEW YORK, 2013-10-17 14:30 CEST (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that abstracts highlighting Zerenex(tm) (ferric citrate coordination complex), the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, have been s ...


17.10.2013

ISBioTech Fall Meeting: Featured Presentation by Dr. Jeffrey A. Shaman, GENEWIZ, Inc.

SOUTH PLAINFIELD, NJ -- (Marketwired) -- 10/10/13 -- , leading global genomic service provider, will join the ISBioTech First Fall Meeting next week in Rosslyn, Virginia, with a featured presentation by Dr. Jeffrey A. Shaman, Business Development Lead, Translational Genomics.Speaking about detection and identification of cell and virus bank contamination, Dr. Shaman will discuss relevant concerns and challenges presented by biopharmaceutical banks. He will further review study data suggesting t ...


10.10.2013

DGAP-News: Keryx Biopharmaceuticals Announces FDA Acceptance for Filing of Zerenex(TM) New Drug Application

Keryx Biopharmaceuticals, Inc. 08.10.2013 14:30 --------------------------------------------------------------------------- NEW YORK, 2013-10-08 14:30 CEST (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that its New Drug Application (NDA) for Zerenex(tm) (ferric citrate coordination complex) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance for filing of the NDA indicates the determination by the FDA that the applicat ...


08.10.2013

DGAP-News: Keryx Biopharmaceuticals, Inc. Announces Appointment of Daniel P. Regan to Board of Directors

Keryx Biopharmaceuticals, Inc. 04.10.2013 14:30 --------------------------------------------------------------------------- Former Global General Manager, Senior Vice President of the Renal Franchise at Genzyme (Sanofi) Brings Key Renal Commercialization Expertise to Keryx NEW YORK, 2013-10-04 14:30 CEST (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced the appointment of Daniel P. Regan to the Company's Board of Directors. Daniel P. Regan, 49, joins th ...


04.10.2013

DGAP-News: Keryx Biopharmaceuticals Announces Appointment of Douglass H. Laidlaw, Ph.D., as Director, Medical Affairs

Keryx Biopharmaceuticals, Inc. 02.10.2013 14:30 --------------------------------------------------------------------------- Formerly National Director, Medical Science Liaisons of the Renal Division at Genzyme/Sanofi NEW YORK, 2013-10-02 14:30 CEST (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the &# ...


02.10.2013

Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

NEW YORK, NY -- (Marketwired) -- 08/14/13 -- TriMarkPublications.com cites in its newly published " and Biosimilars World Markets" report that the global drugs market will jump to over $220 billion by 2019. For more information, visit: ., also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patien ...


14.08.2013

Global Market for Bioseparation Systems for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018

NEW YORK, NY -- (Marketwired) -- 08/13/13 -- TriMarkPublications.com cites in its new report, " for Global Biopharmaceutical Markets," that the global market for for biopharmaceutical manufacturing will jump to $6 billion by 2018. While North America and Europe will continue to account for a significant share of revenue, the emerging countries of China, India, Brazil and Russia are rapidly increasing share, growing at a CAGR of 22%. For more information, visit: .The demand for single ...


13.08.2013

Avantor Performance Materials Expands Distribution Arrangement With VWR International, LLC for Pharmaceutical Production Chemicals in Europe, Middle East and Africa

CENTER VALLEY, PA -- (Marketwired) -- 07/17/13 -- Avantor™ Performance Materials, a global manufacturer of performance materials and chemicals, today announced it has expanded its arrangement with for distribution of its portfolio in the Europe, Middle East and Africa (EMEA) region.VWR is a global solutions provider of laboratory supplies, equipment and services, with worldwide sales in excess of $4.1 billion in 2012.is a global resource for biopharmaceutical and pharmaceutical manufacturers ...


17.07.2013

Morria Announces Corporate Trade Name Change to Celsus Therapeutics and the Appointment of Dr. Gur Roshwalb as Chief Executive Officer

NEW YORK, NY and LONDON -- (Marketwire) -- 03/05/13 -- Morria Biopharmaceuticals Plc. (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced today that it has changed its trade name, and subject to shareholder approval its corporate name, to Celsus Therapeutics (the "Company"); and has appointed Gur Roshwalb, MD, as Chief Executive Officer. Celsus Therapeutics is focused on the development of a novel platform of first-in-class multi-functional anti-inflammato ...


05.03.2013

Taglich Brothers Initiates Coverage on CEL-SCI Corporation

NEW YORK, NY -- (Marketwire) -- 03/04/13 -- . announces it initiated coverage of .(NYSE MKT: CVM), headquartered in Vienna, Virginia, is a development stage biopharmaceutical company focused on unique immunotherapies that address unmet needs in significant patient populations.In recent years, the company's R&D has centered on immunotherapy for head and neck cancer, which now absorbs practically all of its R&D spending. Product development includes work on LEAPS (igand pitope ntigen ...


04.03.2013

LifeSci Advisors Initiates Coverage of Navidea Biopharmaceuticals

NEW YORK, NY -- (Marketwire) -- 02/11/13 -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the healthcare sector, today announced that it has initiated coverage of Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals. In 2011 and 2012, Navidea engaged in strategic business development activities and carved out a strategic niche effectively transforming itself into ...


11.02.2013

Morria Biopharmaceuticals Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer

NEW YORK, NY -- (Marketwire) -- 01/23/13 -- Morria Biopharmaceuticals Plc (the "Company"), an emerging growth biopharmaceutical company focused on developing novel first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that Dr. Alan Harris has joined the Company full time as Chief Medical Officer. Dr. Harris was initially recruited to Morria in July 2012 in a part time capacity. He will develop and lead the clinical development programs for Morria's Mul ...


23.01.2013

New Products to Add One Hundred Billion Dollars of Value to Pharma Market: Kalorama

NEW YORK, NY -- (Marketwire) -- 08/07/12 -- New products will add $100 billion to an ailing global pharmaceutical market by 2016, according to Kalorama Information. The says there are an estimated 724 projects in development from the top 50 companies which have the potential to augment the total pharmaceutical market. The finding was made in Kalorama Information's latest survey of the pharmaceutical industry: "."While not all products in development will be approved and market ...


07.08.2012

Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board

LONDON and NEW YORK, NY -- (Marketwire) -- 07/18/12 -- Morria Biopharmaceuticals Plc., a biopharmaceutical company focused on developing novel, first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that it has appointed Charles Serhan Ph.D. to its Scientific Advisory Board (SAB). Professor Serhan is internationally acknowledged as a leading authority in the field of inflammation and will bring to Morria outstanding academic achievements and impressive experience in t ...


18.07.2012

Biopharmaceutical Manufacturing Trends Toward Leaner, Smaller and More Cost-Effective Facilities, an Industrial Info News Alert

SUGAR LAND, TX -- (Marketwire) -- 06/21/12 -- Researched by Industrial Info Resources (Sugar Land, Texas) -- As the matures, so do planning strategies for production facilities. The industry is seeking ways to build these manufacturing plants at a quicker pace with less complexity, but with high returns on capital investments. This mindset has led to the emergence of non-traditional construction methodologies, as well as equipment reconfigurations and new technologies.For details, view the en ...


21.06.2012

Pacgen Announces Name Change and New Trading Symbol

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 04/30/12 -- Pacgen Biopharmaceuticals Corporation (TSX VENTURE: PGA) ("Pacgen" or the "Company") announced today that it has received the TSX Venture Exchange acceptance to proceed with the change of its name to "Pacgen Life Science Corporation". The Company will begin trading under its new name and stock symbol ("PBS") on May 1, 2012.The change of the Company's name from "Pacgen Biopharmaceuticals ...


30.04.2012

Developer of New Treatment for Severe Asthma Episodes Expects Phase 2 Clinical Trial Results Soon

LOS ANGELES, CA -- (Marketwire) -- 04/19/12 -- In an exclusive Expert Briefing at BioMedReports, Yuichi Iwaki, M.D., Ph.D., the Founder, President and Chief Executive Officer of MediciNova, Inc. (NASDAQ: MNOV) tells investors about a promising treatment approach aimed at meeting the need for novel treatments for patients suffering from acute exacerbations of asthma (AEA), a long-lasting and severe form of asthma episode in which symptoms are unresponsive to initial bronchodilator or corticoste ...


19.04.2012

Taleo to Become UCB's Partner for Global Recruiting Project

DUBLIN, CA -- (Marketwire) -- 03/20/12 -- Taleo Corporation (NASDAQ: TLEO), a global leader of SaaS-based solutions, today announced that global biopharmaceutical leader UCB has chosen Taleo's Recruiting and Reporting products to improve its talent intelligence and support a global revamp of its recruitment processes.UCB is a global biopharma company with a team of more than 8,500 employees, a strong market presence in more than 40 countries, and numerous strategic partnerships across th ...


20.03.2012

Pharmaceutical Outsourcing Launches Redesigned Website Focused on Improved User Experience and Greater Product and Service Visibility

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/13/12 -- , the journal of pharmaceutical and biopharmaceutical contract services and a business unit of , today announced the launch of their newly redesigned website, ."At Pharmaceutical Outsourcing, we're always looking for ways to grow our editorial and provide a more comprehensive resource," said Nigel Russell, General Manager of Pharmaceutical Outsourcing. "The additions we've made allow pharmaceutical decision makers a ...


13.03.2012

Biotechnology Companies Will Increase R&D Outsourcing and Shift It Overseas, Finds Booz & Company Study

SAN FRANCISCO, CA -- (Marketwire) -- 03/07/12 -- As biopharmaceutical companies look to cut costs and improve speed-to-market, more of them plan to outsource R&D and clinical trials and shift this work overseas to places such as China and India, finds a survey released today by global consulting firm .This study confirms that outsourcing will become an increasingly important part of the competitive landscape and provides key insights into why and how the outsourcing process will radically ...


07.03.2012

Pacgen Appoints Peter Sheu as COO

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 03/06/12 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) is pleased to announce the appointment of Mr. Peter Sheu as Chief Operating Officer ("COO"). Mr. Sheu will oversee and implement Pacgen's business development programs. His responsibilities will include strategic planning, formulating and negotiating joint venture and partnership agreements, establishing business rela ...


06.03.2012

Pacgen Expands PAC-113 License

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/30/12 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that the Company has signed an amendment to its license agreement with Demegen, Inc., to expand its exclusive worldwide rights and license to PAC-113 for additional indications, including vaginal, dermatological and ophthalmic applications. There was no payment associated with the amendment license agreement. All oth ...


30.01.2012

Pacgen Closes Private Placement Financing

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/25/12 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it has closed its previously announced private placement (the "Private Placement") of 5,376,350 common shares to CurieMed Corporation. The common shares are issued at $0.0558 per common share, for aggregate subscription proceeds of $300,000.All securities issued pursuant to the Private Placement will b ...


25.01.2012

Pacgen Reports on Private Placement

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/12/12 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that it will be complete its previously announced private placement (the "Private Placement") of 5,376,350 common shares to CurieMed Corporation (CurieMed") upon obtaining regulatory approval. The common shares will be issued at a subscription price of $0.0558 per share, for aggregate subscription proc ...


12.01.2012

Pacgen Reports on Annual and Special Shareholder Meeting

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 01/10/12 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that all resolutions presented at the Company's annual general and special shareholder meeting on December 28, 2011 were approved. These resolutions passed at the meeting include the following items:The Company currently anticipates that the Private Placement will be completed on or about January 12, 2012. Compl ...


10.01.2012

Chelsea Therapeutics Selects StayinFront for New CRM Initiative

FAIRFIELD, NJ -- (Marketwire) -- 01/04/12 -- ., a leading global provider of customer relationship management systems and mobile sales force effectiveness tools, announced today that Chelsea Therapeutics has selected the mobile platform for their new sales force. Management will use ®, StayinFront's SaaS-based CRM and analytics solution, to monitor and manage field performance.Chelsea Therapeutics, a biopharmaceutical development company, is deploying iPads across its newly formed field ...


04.01.2012

Green Room Public Relations Hires Jennifer Bryda Brennan and Melissa Beglin

CAMBRIDGE, MA -- (Marketwire) -- 01/04/12 -- , a specialty agency focused on healthcare public relations and media strategy, has hired Melissa Beglin and Jennifer Bryda Brennan as Public Relations Managers. Both will be supporting the agency's burgeoning life science practice with a focus on global oncology clients."As Green Room PR projects steep growth well into 2012, these newly created positions will expand foundational support for our hybrid model and help maximize efficiencies, ...


04.01.2012

Green Room Public Relations Expands, Launches Cambridge Office

CAMBRIDGE, MA -- (Marketwire) -- 12/19/11 -- , a specialty agency focused on healthcare media and public relations strategy, announces the opening of its second office in Cambridge, Massachusetts. Located at 195 Binney Street in the city's Kendall Square section, the office will serve the agency's growing roster of local clients and as a base for expansion into the burgeoning life science industry hub.Green Room partners and , who are communications and healthcare industry veterans w ...


19.12.2011

Promosome Announces the Appointments of Edward R. Robinson and Loren A. Busby to Its Board of Managers

NEW YORK, NY -- (Marketwire) -- 11/22/11 -- Promosome LLC, a privately held biotechnology company specializing in innovative technologies related to the regulation of protein synthesis, has announced the expansion of its Board of Managers. To further augment its corporate structure and support for its technology commercialization efforts, Promosome is pleased to announce the addition of Mr. Edward R. Robinson and Ms. Loren A. Busby."We are pleased to welcome Ed and Loren to our Board. The ...


22.11.2011

Pacgen Appoints Dr. Ming S. Liu as CEO

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/25/11 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) announced today that Ming S. Liu, Ph.D. has joined the Company as Chief Executive Officer ("CEO") and director. Dr. Liu replaces Dr. YC Lee as CEO as Pacgen continues to implement its previously announced corporate transformation.Dr. Liu possesses more than 15 years of diversified experience in bio-products development, sa ...


25.10.2011

Pacgen Announces Private Placement Financing

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 09/02/11 -- Pacgen Biopharmaceuticals Corporation (the "Company" or "Pacgen") (TSX VENTURE: PGA) announced today that it has reached an agreement in principle with CurieMed Corporation ("CurieMed") with respect to a non-brokered private placement (the "Financing") of $300,000 of common shares ("Common Shares"). Completion of the Financing is subject to satisfactory completion of certain conditions, ...


02.09.2011

Pacgen Reports Annual Financial Results

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 08/05/11 -- Pacgen Biopharmaceuticals Corporation ("Pacgen" or the "Company") (TSX VENTURE: PGA) reported financial results from its fiscal year ended March 31, 2011 ("Fiscal 2011"). The Company recorded a net loss of $421,468 ($0.01 per common share), compared to a net loss of $1,625,315 ($0.09 per common share) for the preceding fiscal year ended March 31, 2010 ("Fiscal 2010"). The decrease in net loss by ...


05.08.2011

Vela Laboratories Announces Renewal of GMP Certificate for Analytical and Quality Control Laboratories

Vienna, Sept. 8, 2010 – Vela Laboratories, a provider of analytical services to the global biopharmaceutical industry, announced today the renewal of the GMP certificate for its analytical and Quality Control laboratories until 2013. “We are pleased that Vela Laboratories has its GMP certification renewed, as this achievement will further strengthen our position as a provider to the global pharmaceutical and biotechnology industry,” said Dr. Markus Fido, co-founder and CEO of Vela Laboratories ...


08.09.2010



All members: 9 432
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 47


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.